Table 1.
Biomarkers |
Molecular basis | Predictive value | Detection method | |
Category | Type | |||
Pathological characteristics | Tumor stage | Diagnostic, prognostic and predictive markers | Diagnostic radiology and pathological/cytological examination | |
Lymph node status | ||||
Grade of differentiation | ||||
Anatomy of invasion | ||||
Proliferation markers | Ki67 | Nuclear antigen associated with proliferation | Diagnostic and prognostic markers | IHC |
Cyclins | Regulation of cell cycle phase transition | Diagnostic and prognostic markers | IHC | |
Chromosome abnormalities | p53 | Tumor suppressor gene which shows loss of function | Diagnostic, prognostic and predictive markers | IHC, RT-PCR, FISH |
H-ras, K-ras, N-ras | Membrane-associated GTPase integral to signal transduction cascade, if mutated, causes increased cellular proliferation | Diagnostic, prognostic and predictive markers | IHC, RT-PCR, FISH | |
Telomere length | Pathologic telomere length dynamics | Diagnostic and prognostic markers | RT-PCR, Flow cytometry | |
Telomerase activity | Maintenance of telomeres and therefore chromosomal length | Diagnostic and prognostic markers | TRAP assay | |
enables progression through successive cell cycles | ||||
Hypoxia-regulated genes | HIF-1 | HIF-1 transcription factor complex stabilized in hypoxic conditions, leading to transcription of hypoxia-regulated genes | Diagnostic and prognostic markers | IHC |
Glut-1 | Increased Glut-1 expression caused by malignant transformation and upregulated by hypoxia. Promotes switch to anaerobic glycolysis to support hypoxic tumor | Diagnostic and prognostic markers | IHC | |
Angiogenesis | VEGF | Angiogenic growth factor | Prognostic and predictive markers | IHC, FISH, immunoassay |
PD-ECGF | Angiogenic growth factor with thymidine phosphorylase activity | Prognostic and predictive markers | IHC | |
Vascularity | New vasculature supports tumor growth | Prognostic and predictive markers | IHC staining for endothelial receptors e.g., CD31, CD34, von Willebrand (factor VIII) combined with measurement of ICD or MVD using digital image analysis techniques | |
Epigenetics | Aberrant DNA hypermethylation | Inactivation of key tumor suppressor genes including APC, ATM, BMP3, CDKN2A, SFRP2, GATA4, GSTP1, HLTF, MLH1, MGMT, NDRG4, RASSF2A, SFRP2, TFPI2, VIM, and WIF1 | Diagnostic, prognostic and predictive markers | PCR-based methods and Pyrosequencing |
Aberrant DNA hypomethylation | Lids to chromosomal instability and global loss of imprinting | Diagnostic and prognostic markers | PCR based methods and Pyrosequencing | |
Tumor specific expression patterns | Gene expression patterns | Unique signature of the dysregulated genes/pathways at different forms and stages of CRC | Diagnostic, prognostic and predictive markers | Array-based methods, NGS, RT-PCR |
MicroRNA expression patterns | Unique signature of the dysregulated microRNAs at different forms and stages of CRC | Diagnostic, prognostic and predictive markers | Array-based methods, NGS, RT-PCR |
FISH: Fluorescent in-situ hybridization; HIF-1: Hypoxia inducible factor-1; HPLC: High pressure liquid chromatography; ICD: Intercapillary distance; IGF-1: Insulin growth factor-1; IHC: Immunohistochemistry; MVD: Microvessel density; NGS: Next generation sequencing; PD-ECGF: Plateletderived endothelial cell growth factor; RT-PCR: Reverse transcription–polymerase chain reaction; RIA: Radioimmunoassay; VEGF: Vascular endothelial growth factor.